MEDPLUS

** Shares of Medplus Health Services MEDP.NS fall 4.8% to 874 rupees

** Stock marks steepest intraday pct loss since January 14

** Nomura maintains "buy" rating; cuts price target to 1,030 rupees from 1,050 rupees

** New PT implies 12.1% upside to last close, compared to previous PT's 14.2% upside

** Says Q1 results missed estimates due to higher employee expenses

** Brokerage lowers fiscal 2026 and 2027 operating EBITDA estimates by ~15%/22%, factoring in slower revenue growth and elevated overheads

** MEDP rated "strong buy" by six analysts on average; median target price is 1,087.5 rupees – data compiled by LSEG

** Stock up 5.2% YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

Feb 19 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• STAY ORDER GRANTED AGAINST DEMAND OF 18.9 MILLION RUPEES

Source text: ID:nBSE2P9g0R

Further company coverage: MEDP.NS

(([email protected];;))

Jan 31 (Reuters) - India's MedPlus Health Services MEDP.NS reported a surge in third-quarter profit on Friday, driven by store expansions and strong demand for over-the-counter medicines.

The company's consolidated net profit more than tripled to 458.8 million rupees ($5.3 million) in the quarter ended Dec. 31.

MedPlus continued to benefit from strong sales of products under its private label brands in both the pharmaceuticals and consumer wellness categories, which analysts say contribute more to its margins.

The company's revenue from operations rose 8.3% to 15.61 billion rupees, led by an 8% jump in its retail business.

While MedPlus does not break up its revenue from OTC medicines and devices, etc, they are all part of its retail business, which makes up nearly all of the company's revenue.

The company currently has more than 4,000 outlets across the country, trailing only Apollo Pharmacy's count of nearly 6,000 stores. Last year, MedPlus said it plans to open 600 stores to increase its presence in smaller cities.

MedPlus competes with Reliance Industries' RELI.NS Netmeds and Apollo Pharmacy, both of which are unlisted, among other retail pharmacies in the Indian OTC drug retail market.

($1 = 86.5830 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

Jan 7 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• OPTIVAL HEALTH SOLUTIONS RECEIVES DRUG LICENSE SUSPENSION ORDER

Source text: ID:nBSE2nPfJT

Further company coverage: MEDP.NS

(([email protected];;))

** Shares of MedPlus Health Services MEDP.NS fall as much as 4.3% to 811 rupees before recovering slightly; last down 3.8%

** Co's unit Optival Health Solutions gets suspension order of drug license for stores in Karnataka and Maharashtra

** Stock on track for second-sharpest intraday fall in 2024

** Avg rating of six analysts is a "strong buy" and median PT is 915 rupees, ~12% higher than current price - LSEG data

** Stock trims YTD gains to around 9%

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Dec 19 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - OPTIVAL HEALTH SOLUTIONS RECEIVES DRUG LICENSE SUSPENSION ORDER

Source text: ID:nBSE9dL6xb

Further company coverage: MEDP.NS

(([email protected];))

Nov 28 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - UNIT GOT ONE SUSPENSION ORDER OF DRUG LICENSE FOR FOUR DAYS AT ONE STORE

• MEDPLUS HEALTH SERVICES - POTENTIAL REVENUE LOSS OF 250,000 RUPEES FROM ORDER

Source text: ID:nNSE15b7k9

Further company coverage: MEDP.NS

(([email protected];))

Nov 18 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• PI OPPORTUNITIES FUND-I SOLD 6.9 MILLION SHARES OF MEDPLUS HEALTH SERVICES AT 700 RUPEESPER SHARE VIA BULK DEAL - EXCHANGE DATA

• SBI MUTUAL FUND SOLD 1 MILLION SHARES OF MEDPLUS HEALTH SERVICES AT 700 RUPEESPER SHARE VIA BULK DEAL - EXCHANGE DATA

Source text: [ID:]

Further company coverage: MEDP.NS

(([email protected];;))

** Shares of MedPlus Health Services MEDP.NS rise as much as 7.4% to 724.95 rupees

** MEDP on Tuesday reported its Q2 consol net profit to more than doubled to 387.4 mln rupees ($4.6 mln); rev from ops rose ~12% Y/Y

** Co's retail business, which accounts for nearly all of its revenue, rose 11.3% Y/Y

** More than 1.5 mln shares change hands, 6.5x of 30-day avg

** Avg rating of six analysts equivalent to "strong buy", median PT is 840 rupees - LSEG data

** Stock down 6.5% YTD

($1 = 84.4000 Indian rupees)

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Nov 12 (Reuters) - India's MedPlus Health Services MEDP.NS reported a sharp jump in second-quarter profit on Tuesday, propelled by strong demand for over-the-counter (OTC) medicines.

The company reported consolidated net profit of 387.4 million rupees ($4.6 million) for the quarter ended Sept. 30, compared to 145.6 million rupees a year ago.

Its revenue from operations rose 12% to 15.76 billion rupees, led by an about 11% jump in its retail business, which accounts for nearly all of its total revenue.

The company did not specify the sales break-up of over-the-counter and prescription medicines, both of which are part of the retail business.

Drugmakers Mankind Pharma's MNKI.NS and Cipla's CIPL.NS domestic revenues were boosted by strong demand for OTC medications, the companies said in their second-quarter earnings statements.

MedPlus Health said in September that it plans to increase its presence in tier-2 cities by opening 600 new stores over the next three years.

The company currently has more than 4,000 outlets in the country, just behind Apollo Pharmacy, which has more than 6,000 stores.

It also said it is focussing on increasing the scalability of products under its own private label in both pharmaceuticals and consumer wellness categories, which according to analysts contributes more to its margins.

MedPlus competes with Reliance Industries' RELI.NS Netmeds and Apollo Pharmacies, both of which are unlisted, among other retail pharmacies in the Indian OTC drug retail market.

($1 = 84.3670 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru and Varun H K)

(([email protected]; 8800437922;))

Oct 31 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• UNIT RECEIVED FIVE SUSPENSION ORDERS OF DRUG LICENSE

Source text: ID:nBSEc5fS70

Further company coverage: MEDP.NS

(([email protected];;))

Aug 20 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - UNIT RECEIVED TWO SUSPENSION ORDERS OF DRUG LICENSE

Source text for Eikon: ID:nNSE5Vk96x

Further company coverage: MEDP.NS

(([email protected];))

Aug 2 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES Q1 CONSOL NET PROFIT 143.6 MILLION RUPEES

• MEDPLUS HEALTH SERVICES Q1 CONSOL REVENUE FROM OPERATIONS 14.89 BILLION RUPEESS

Source text for Eikon: ID:nBSE1XHvFg

Further company coverage: MEDP.NS

(([email protected];))

July 24 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - UNIT GOT 3 DAYS SUSPENSION ORDER FOR TRICHY STORE

Further company coverage: MEDP.NS

(([email protected];))

July 5 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• RECEIVED STAY ORDER AGAINST EARLIER SUSPENSION ORDER

Further company coverage: MEDP.NS

(([email protected];))

June 28 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• RECEIVED TWO DAYS SUSPENSION ORDER OF DRUG LICENSE FOR A STORE SITUATED AT HYDERABAD

• POTENTIAL REVENUE LOSS OF 0.15 MILLION RUPEES DUE TO THE SUSPENSION ORDER

Further company coverage: MEDP.NS

(([email protected];))

** Shares of MedPlus Health Services MEDP.NS down 2.5% to 712.8 rupees

** Stock among few losers amid jump in broader markets .BO

** The retail pharmacy co says its unit got four days suspension order for store in Warangal, Telangana

** Stock on track to log biggest one-day drop since early-Feb

** Analysts' avg rating on stock is equivalent of "Buy", their median PT is 855 rupees, per LSEG data

** Including session's losses, stock down ~5% YTD

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

BENGALURU, May 28 (Reuters) - India's MedPlus Health Services MEDP.NS reported a rise in fourth-quarter profit on Tuesday, driven by retail sales.

MedPlus, which sells online and in retail stores, said consolidated net profit climbed 25.6% year-on-year to 333.96 million rupees ($4 million) for the three months to March 31.

Analysts expect the retail pharmaceutical sector to see strong growth in the near term and an increasing market share for organised players such as MedPlus. Store network expansion and an uptick in branded prescription medicines are expected to boost sales further.

New drug launches and improving medical infrastructure have also improved access to these medicines, driving sales of retail pharmacies.

MedPlus said revenue from operations rose nearly 19% to 14.90 billion rupees.

Revenue from its retail business, which constituted 98% of its net sales, jumped more than 18%, while revenue from its diagnostics business surged 94.6%.

Expenses rose 17.6%, mainly due to higher procurement costs of medicines it sells.

MedPlus competes with Reliance-owned RELI.NS Netmeds and Apollo Pharmacies among other retail pharmacies in the Indian OTC drugs market.

Shares of MedPlus closed 1.6% lower ahead of the result.

($1 = 83.1700 Indian rupees)

(Reporting by Kashish Tandon and Varun Hebbalalu in Bengaluru; Editing by Sohini Goswami)

(([email protected];))

April 11 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• UNIT RECEIVED SUSPENSION ORDERS FROM DRUGS AND CONTROL AUTHORITIES

• POTENTIAL REVENUE LOSS OF SUSPENSION ORDERS AGGREGATES TO 1.7 MILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: MEDP.NS

(([email protected];))

March 21 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• RECEIVED A SUSPENSION ORDER FROM DRUGS AND CONTROL AUTHORITIES

Source text for Eikon: ID:nNSE4MjZdG

Further company coverage: MEDP.NS

(([email protected];))

** Shares of MedPlus Health Services MEDP.NS fall ~2% to 699 rupees

** Pharmacy retailer said its board has decided not to proceed with a fund raise, for which it had received shareholders' approval on Nov. 30

** Fund raise deferred as board decided to stall expansion plans of its diagnostics division beyond Hyderabad until pilot project turns profitable

** Avg rating of five analysts on MEDP is "strong buy;" median PT is 980 rupees - LSEG data

** Stock down 6.8% YTD after rising 22% in 2023

(Reporting by Kashish Tandon)

(([email protected]))

MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - UNIT GETS SUSPENSION ORDER FROM DRUGS AND CONTROL AUTHORITIES, BANGALORE

• MEDPLUS HEALTH SERVICES LTD - UNIT GETS ORDER FOR TEMPORARILY SUSPENDING OPERATIONS OF A STORE FOR 2 DAYS

Source text for Eikon: [ID:]

Further company coverage: MEDP.NS

Feb 16 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• TO DISCUSS MANAGEMENT RECOMMENDATION TO NOT PROCEED WITH APPROVAL FOR QUALIFIED INSTITUTIONAL PLACEMENT

Source text for Eikon: ID:nBSE16Z2Pm

Further company coverage: MEDP.NS

(([email protected];;))

Feb 2 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES DEC-QUARTER CONSOL NET PROFIT 137.3 MILLION RUPEES, REVENUE FROM OPERATIONS 14.41 BILLION RUPEES

Further company coverage: MEDP.NS

(([email protected];;))

Jan 24 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• SUBSIDIARY COMPANY RECEIVED SUSPENSION ORDER OF DRUG LICENSE FOR ITS STORE

Source text for Eikon: ID:nBSE4glX1X

Further company coverage: MEDP.NS

(([email protected];))

Jan 15 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• UNIT RECEIVED ORDER FROM DRUG LICENSING AUTHORITY, MAHABOOBNAGAR

• ORDER FOR SUSPENSION OF DRUG LICENSE FOR 7 DAYS

Source text for Eikon: ID:nNSEc7zHR6

Further company coverage: MEDP.NS

(([email protected];))

Jan 11 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• UNIT RECEIVED ORDER FROM DRUG LICENSING AUTHORITY, DRUG CONTROL ADMINISTRATION, RAJAMAHENDRAVARAM

• UNIT GOT ORDER FOR SUSPENSION OF DRUG LICENSE FOR 3 DAYS

• THERE IS NO MAJOR FINANCIAL IMPACT, CO TAKING CORRECTIVE ACTION

Source text for Eikon: ID:nBSE8q1xYW

Further company coverage: MEDP.NS

(([email protected];))

Jan 5 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - RECEIVED ORDERS FROM DRUG SALES LICENSING AUTHORITY, DRUG CONTROL ADMINISTRATION

• MEDPLUS HEALTH SERVICES LTD - UNIT RECEIVED ORDERS DRUG CONTROL ADMINISTRATION

• MEDPLUS HEALTH SERVICES LTD - UNIT RECEIVED ORDERS DRUG CONTROL ADMINISTRATION FOR SUSPENSION OF DRUG LICENSE

Source text for Eikon: ID:nBSE7QnZFZ

Further company coverage: MEDP.NS

(([email protected];;))

Jan 2 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• RECEIVED ORDERS FROM DRUG CONTROL ADMINISTRATION FROM VARIOUS LOCATIONS

• NO MAJOR FINANCIAL IMPACT, CO TAKING CORRECTIVE ACTION

Source text for Eikon: ID:nBSE2k4t98

Further company coverage: MEDP.NS

(([email protected];))

Dec 25 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• UNIT RECEIVED AN ORDER FROM DRUGS AND CONTROL AUTHORITY, CHENNAI, TAMIL NADU

• ORDER FOR SUSPENSION OF DRUG LICENSE

• NO MAJOR FINANCIAL IMPACT DUE TO THE ORDER

Source text for Eikon: ID:nBSE3JXDPk

Further company coverage: MEDP.NS

(([email protected];;))